INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

Huntsman Carole sold MDGL

Chief Commercial Officer · MADRIGAL PHARMACEUTICALS, INC. · Common Stock

Side
SELL
Value
$282K
Shares
570
Price
$494.59
Executed
Jan 26, 2026
Disclosed
Jan 26, 2026
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Jan 26 executedJan 26, 2026 disclosed

MDGL · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
25/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+11 / 25

    $282K reported value · 5.9% of prior position

  • Filing timing0 / 15

    Disclosed 0 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering+10 / 15

    2 other actors traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · MDGL

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    4
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$652K
    1,202 sh
    		Sep 11, 2026Sep 11, 2026
    traded Sep 11, 2026
    		+0dSEC FORM 4

    Evidence

    1
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$199K
    368 sh
    		Sep 11, 2026Sep 11, 2026
    traded Sep 11, 2026
    		+0dSEC FORM 4

    Evidence

    4
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$415K
    761 sh
    		Sep 11, 2026Sep 11, 2026
    traded Sep 11, 2026
    		+0dSEC FORM 4

    Evidence

    4
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$837K
    1,539 sh
    		Sep 11, 2026Sep 11, 2026
    traded Sep 11, 2026
    		+0dSEC FORM 4

    Evidence

    7
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$345K
    644 sh
    		Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    		+2dSEC FORM 4

    Evidence

    4
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$212K
    396 sh
    		Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    		+2dSEC FORM 4

    Evidence

    1
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$66K
    120 sh
    		Sep 11, 2026Sep 11, 2026
    traded Sep 11, 2026
    		+0dSEC FORM 4

    Evidence

    4
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$184K
    347 sh
    		Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    		+2dSEC FORM 4

    Evidence

    7
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$344K
    640 sh
    		Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    		+2dSEC FORM 4

    Evidence

    7
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$558K
    1,040 sh
    		Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    		+2dSEC FORM 4

    Evidence

    4
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$87K
    160 sh
    		Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    		+2dSEC FORM 4

    Evidence

    4
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$196K
    368 sh
    		Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    		+2dSEC FORM 4

    Evidence

    7
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$273K
    512 sh
    		Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    		+2dSEC FORM 4

    Evidence

    0
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$32K
    60 sh
    		Sep 11, 2026Sep 11, 2026
    traded Sep 11, 2026
    		+0dSEC FORM 4

    Evidence

    7
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$277K
    522 sh
    		Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    		+2dSEC FORM 4

    Evidence

    4
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$69K
    131 sh
    		Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    		+2dSEC FORM 4

    Evidence

    7
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$273K
    505 sh
    		Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    		+2dSEC FORM 4

    Evidence

    4
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$116K
    215 sh
    		Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    		+2dSEC FORM 4

    Evidence

    7
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$280K
    520 sh
    		Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    		+2dSEC FORM 4

    Evidence

    4
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$196K
    362 sh
    		Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001628280-26-003482
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 26, 2026
    Published
    Jan 26, 2026
    Ingested by INSIDER
    Nov 5, 04:20 UTC
    Last re-read
    Nov 5, 04:20 UTC

    Extracted facts

    Filer
    Huntsman Carole
    Role
    Chief Commercial Officer
    Transaction
    Open-market saleAs filed: “S”
    Asset
    MADRIGAL PHARMACEUTICALS, INC.
    Ticker
    MDGL
    Shares
    570
    Price per share
    $494.59
    Value
    $281,916
    Execution date (reported)
    Jan 26, 2026
    Owned after transaction
    9,122 shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    0

    Calculation

    Value = shares × reported price per share

    • Shares: 570
    • Price: $494.59

    = $281,916

    What this establishes

    Huntsman Carole filed this Form 4 reporting a open-market sale of MDGL on Jan 26, 2026. It became public on Jan 26, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Commercial Officer
    Huntsman Carolecik:0002001571
    Issuer
    MADRIGAL PHARMACEUTICALS, INC.cik:0001157601

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.